All patients whose tumor harbored PD-L1MUT (5/20 cases) achieved complete response to PD-1 checkpoint inhibitor pembrolizumab, demonstrating sensitivity of 100% as a biomarker of response. This evidence concerns the gene PDCD1 and neoplasm.